This study evaluated the outcomes of urethroplasty performed in male patients by a single surgeon. A retrospective review of male patients who underwent substitution urethroplasty by a single surgeon was performed.
Lymph node metastases are found in approximately 15% of patients treated by radical prostatectomy (RP). Although nodal involvement is clearly a poor prognostic sign, it is not an inevitable harbinger of recurrence: about one in three patients with positive lymph nodes remain recurrence free at long-term follow-up even in the absence of post-operative treatment.1 This […]
Mesh erosion following stress urinary incontinence (SUI) surgery is a rare but increasingly occurring complication. In 2018 a temporary ban was introduced in the UK following an alarming rise in reported cases of mesh related complications. Mesh related complications can cause huge morbidity to patients and hence it is important to carefully consider management options. […]
Upper tract urothelial carcinoma (UTUC) is a common and lethal malignancy. Patients diagnosed with this illness often face invasive workups, morbid therapies, and prolonged post-operative surveillance.
{{header-clinical-trials-navigation}} An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations Condition: Urothelial Carcinoma Intervention: Drug: Derazantinib Drug: Atezolizumab (drug supplied by Hoffmann-La Roche) Purpose: The purpose of this study is to evaluate efficacy of derazantinib single-agent or derazantinib-atezolizumab in combination in patients with advanced […]
The sequential use of a number of new agents (NAs) have improved the overall survival (OS) of patients with metastatic castration-resistant prostate cancer whose disease progresses after docetaxel (DOC) treatment.
Predictive models that take race into account like the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPT RC) and the new Prostate Biopsy Collaborative Group (PBCG) RC have been developed to equitably mitigate the overdiagnosis of prostate specific antigen (PSA) screening.
In our center, until 2018, MRI-targeted biopsy was underused. Since January 2018, we systematically performed MRI-targeted biopsy for suspicious PI-RADS ≥ 3 lesions in accordance to the recent guidelines.
Immuno-oncology (IO) therapies have changed the treatment standards of metastatic renal cell carcinoma (mRCC). However, the effectiveness of targeted therapy following discontinuation of IO therapy in real-world settings has not been well studied.
A histological grading system of chromophobe renal cell carcinoma (chRCC) is highly desirable to identify approximately 5-10% of tumors at risk for progression. Validation studies failed to demonstrate a correlation between the four-tiered WHO/ISUP grade and outcome.
